145 results about "Antigen recognition" patented technology

The invention belongs to the technical field of data processing, and discloses a dynamic configurable data cleaning method and system based on big data, and the method comprises the steps: collecting a heterogeneous data source, and carrying out the access of the heterogeneous data source in combination with a data source adaptive interface; identifying an abnormal mode in the heterogeneous data source and encoding the abnormal mode into an antigen fingerprint by using a simulated antigen identification memory mechanism; constructing a data value density scoring function based on the antigen fingerprints to obtain a data value density score; constructing a three-dimensional storage topological space according to the data value density score, adopting a lattice migration algorithm, automatically identifying a cold and hot data critical point, triggering hierarchical migration when the temperature of the heterogeneous data source is reduced to a preset temperature threshold value, introducing a thermodynamic diffusion mechanism, and simulating the migration process of the heterogeneous data source in the three-dimensional storage topological space as a thermal diffusion path; and the operation efficiency of the cleaning task is obviously improved.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention provides an anti-TNF (Tumor Necrosis Factor) alpha nano antibody and application thereof, and relates to a nano antibody, polypeptide containing the nano antibody, application of the nano antibody and the like, a variable region in an amino acid sequence of the nano antibody comprises three complementarity determining regions CDR and a framework region FR, the complementarity determining regions CDR comprise a complementarity determining region CDR1, a complementarity determining region CDR2 and a complementarity determining region CDR3, the main sites participating in antigen recognition and binding are RXXXXXE on CDR1 and ATYSDSPWNXXSFYXLSGVGA on CDR3, and the nano antibody and the polypeptide thereof have very high affinity and activity, can specifically recognize and bind TNF alpha, and can be used for adsorption, removal, detection and the like of TNF alpha.

The invention is directed to a conjugate having the general formula (I)Xn—P—YmBo  (I)with X is an detection moiety,P is a spacer unit,Y an antigen recognizing moiety,B an oligonucleotide comprising 2 to 100 nucleotide residuesand n, m, o are independent integers between 1 and 100wherein P and B are covalently bound to Y and X is covalently bound to P and wherein X is erasable.Further, the invention is directed to a library of such conjugates and a method of detecting target cells utilizing the conjugates or the library of conjugates.

Provided is a fusion protein, comprising IL-10 and a transmembrane domain, wherein the fusion protein is expressed on an immune cell, and the immune cell does not comprise a regulatory T cell. Also provided is a modified immune cell, comprising a fusion protein and an antigen recognition receptor, wherein the fusion protein comprises IL-10 and a transmembrane domain, and the immune cell does not comprise a regulatory T cell. Also provided is a use of the fusion protein and the modified immune cell in prevention and / or treatment of diseases.

The present invention relates to immune cells that express immune checkpoint regulators and overcome immune checkpoints, a method for producing the same, and a pharmaceutical composition containing the immune cells. More specifically, the present invention relates to immune cells that are genetically engineered to express an anti-HLA-G soluble scFv that specifically binds to HLA-G, which is an immune checkpoint, together with an antigen recognition receptor, a method for producing the same, and a pharmaceutical composition containing the immune cells. When the anti-HLA-G soluble scFv of the present invention is expressed alone or simultaneously with an antigen recognition receptor in T lymphocytes, natural killer cells, etc., immune cells inhibited by cancer cells expressing immune checkpoints can be activated, and cancer cells can be removed more efficiently. Thereby, activation of endogenous immune cells that have been inhibited by immune checkpoints can also be expected, and thus it can be usefully used as an immunotherapy method for various cancer diseases related to HLA-G.

The invention belongs to the technical field of medical informatics, and discloses an internal medicine disease treatment scheme optimization system and method based on machine learning, and the system comprises a heterogeneous data monitoring module which is integrated with a multi-source heterogeneous medical database through a standard medical API interface, and extracts and obtains internal medicine disease heterogeneous data; the immune response network module simulates an antigen recognition response mode, constructs a treatment scheme antigen representation matrix according to the internal medicine disease heterogeneous data, recognizes abnormal treatment modes through transfer learning, removes invalid treatment schemes or treatment schemes with side effects corresponding to all the abnormal treatment modes, and then obtains historical effective treatment schemes; a neural symbol memory mechanism is adopted, historical effective treatment scheme fragments are stored, and a treatment scheme variant is constructed based on an adversarial generation mechanism; and the accuracy, individuation and safety of a treatment scheme are improved, so that the treatment effect of internal medicine diseases is remarkably improved, side effects and wrong schemes are reduced, and the development of precise medical treatment is promoted.

The invention provides a chimeric antigen receptor for regulating and controlling a signal time sequence and application of the chimeric antigen receptor. The chimeric antigen receptor sequentially comprises a signal peptide, an extracellular domain, a transmembrane domain and an intracellular domain from an N terminal to a C terminal, the extracellular structural domain comprises an antigen recognition region and a hinge region; the intracellular domain comprises a costimulatory signal transduction region and a CD3 [zeta] intracellular region variant; the CD3 [zeta] intracellular region variant comprises three ITAMs, and the arrangement sequence of the ITAMs is ITAM3-ITAM2-ITAM1 from the N end to the C end. Compared with a conventional chimeric antigen receptor containing a wild CD3 zeta intracellular region, the chimeric antigen receptor provided by the invention can significantly enhance the functional activity of immune cells expressing the chimeric antigen receptor, which is specifically embodied in stronger multiplication capacity and durability, and significantly improves the antigen sensitivity and targeted killing efficacy.

Various embodiments of the invention provide binding agents for glypican-3 (GPC3), including antibodies or antigen-binding fragments thereof that bind to GPC3 and antigen recognizing receptors (e.g., CARs) that target GPC3 including cells that express GPC3. Embodiments of the i n vention also provide cells comprising such binding agents such as CAR T-cells, therapeutic compositions comprising such cells and methods of using one or more of the binding agents, cells or therapeutic compositions for the treatment of diseases or disorders associated with GPC3 expression such as various neoplastic diseases or disorders (e.g., hepatocellular carcinoma). Various embodiments of the invention also provide methods and systems for treati ng hepatocellular carcinoma (HCC) utilizing a combi nation of radiofrequency (RF) ablation and GPC3-targeted cell therapy. In certain embodiments, immune modulators, such as checkpoint inhibitors, may be co-administered to potentiate immune responses. Additionally, compositions and kits comprising RF ablation devices and GPC3-targeted cell therapy formulations are provided.

The present invention belongs to the field of data processing technology. The present invention discloses a dynamic and configurable data cleaning method based on big data and a system thereof. The method comprises collecting heterogeneous data sources and accessing the heterogeneous data sources in combination with a data source adapter interface; utilizing a simulated antigen recognition memory mechanism to identify abnormal patterns in the heterogeneous data sources and encode them into antigen fingerprints; constructing a data value density scoring function based on the antigen fingerprint to obtain a data value density score; constructing a three-dimensional storage topological space according to the data value density score, adopting a lattice migration algorithm to automatically identify the critical points of hot and cold data, triggering hierarchical migration when the heterogeneous data source is cooled to a preset temperature threshold, introducing a thermodynamic diffusion mechanism, and simulating the migration process of the heterogeneous data source in the three-dimensional storage topological space as a heat diffusion path; and significantly improving the operating efficiency of the cleaning task.

Disclosed is a nucleic acid encoding a chimeric antigen receptor comprising an extracellular domain including an antigen recognition domain consisting of a fully human single variable heavy chain (VH) domain that binds to a first epitope on B-cell maturation antigen (BCMA), a transmembrane domain, and an intracellular domain including a signaling domain.

Described herein are genetically modified bispecific immune cells such as bicistronic and bivalent immune cells. The bispecific immune cells include an antigen recognition domain that specifically binds a tumor-specific antigen and an antigen recognition domain that specifically binds a radiation-induced cell surface marker. Also described are methods of treating cancer in a subject including administering to the subject a dose of a targeted radionuclide therapy (TRT) agent, and administering to the subject the genetically modified bispecific immune cell.

The present technology provides polypeptides comprising a first immunoglobulin single variable domain (ISVD) binding to albumin, a second ISVD capable of binding to both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell, wherein said first and second ISVD are linked by a protease cleavable linker, and a targeting moiety. The present technology further provides nucleic acids encoding said polypeptides as well as vectors, hosts and methods to produce these polypeptides. Moreover, the present technology relates to methods for treatment making use of the polypeptides according to the present technology.

This invention belongs to the field of antigen recognition technology, specifically relating to an antibody or its antigen-binding fragment that targets and recognizes mCD155, and its applications. The antibody targeting and recognizing mCD155 includes sequences as shown in SEQ ID NO:8 and SEQ ID NO:16 or as shown in SEQ ID NO:24 and SEQ ID NO:32; it has a strong binding affinity to the mCD155-his protein; and CAR-T cells constructed based on this antibody exhibit excellent killing (apoptotic) activity against mCD155-mediated tumors.

The purpose of the present invention is to provide a polypeptide capable of binding to protein L. Provided is a protein L-binding polypeptide comprising amino acid sequence 1, which is L1 sequence (such as the amino acid sequence represented by SEQ ID NO: 1) - antigen recognition sequence 1 - L2 sequence (such as the amino acid sequence represented by SEQ ID NO: 2) - antigen recognition sequence 2 - L3 sequence (such as the amino acid sequence represented by SEQ ID NO: 3) - antigen recognition sequence 3 - L4 sequence (such as the amino acid sequence represented by SEQ ID NO: 4).

The present application relates to a kind of anti-CD276 nanobody, the anti-CD276 nanobody includes complementary determining region CDR and framework region FR;Wherein, the complementary determining region CDR includes complementary determining region CDR1-CDR3;The framework region FR includes framework region FR1-FR5.The anti-human CD276 nanobody provided by the present application has the immunoreaction characteristic with CD276 antigen, and specificity is good, and affinity is high, can be applied to the preparation of CD276 detection reagent or antitumor drug etc., the anti-human CD276 nanobody provided by the present application can be used as the antigen recognition domain of CAR Then the construction of CAR-T cell, it has significant killing effect to the multiple tumor cell lines of expression CD276 antigen;The anti-human CD276 nanobody provided by the present application can be used to detect the expression of CD276 in tumor tissue.

Provided is a modified regulatory T cell capable of recognizing cells of the liver, capable of treating and / or preventing transplant rejection or immune-mediated damage, and capable of promoting regeneration of cells of the liver.SOLUTION: The present invention provides engineered regulatory T cells (Tregs) comprising a chimeric antigen receptor (CAR), wherein said CAR comprises an antigen recognition domain that specifically binds to the asialoglycoprotein receptor (ASGR). The invention also provides a method of promoting liver tissue repair and / or regeneration in a subject, said method comprising administering to said subject a modified Treg comprising a CAR, or a pharmaceutical composition comprising said modified Treg, wherein said CAR comprises a liver-specific antigen recognition domain.SELECTED DRAWING: None

Provided herein are CasX:gNA systems, and compositions and methods relating thereto, the systems comprising CasX proteins, guide nucleic acids (gNAs), and optionally donor template nucleic acids useful for the modification cell genes encoding proteins involved in antigen processing, antigen presentation, antigen recognition, and / or antigen response, as well as methods of producing and using populations of cells comprising these modified genes. In some embodiments, the modified cells further express chimeric antigen receptors (CAR) or engineered T cell receptors (TCR). Such systems are useful for preparing cells for immunotherapy.

Provided are a CD19-targeting humanized antibody and chimeric antigen receptor, and the use thereof. The humanized antibody contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8). The CD19-targeting chimeric antigen receptor contains a CD19-targeting extracellular antigen recognition domain, a hinge region, a transmembrane region, and an intracellular domain, wherein the CD19-targeting extracellular antigen recognition domain contains CD19 VH and CD19 VL which are selected from one of groups 1) to 8).

The invention provides a plasmid for expressing a chimeric antigen receptor (CAR), a gamma delta-T cell and application, and relates to the technical field of biology. According to the plasmid for expressing the CAR, the expression efficiency of various promoters in gamma delta-T cells is compared, the promoter most suitable for the cell type is screened out, and the result shows that the SFFV promoter has the optimal expression performance. Compared with EF1 alpha and NMD, the promoter provided by the invention has higher transduction efficiency. The invention provides a structurally optimized CAR-gamma delta-T cell and a construction method thereof. The CAR structure comprises a combination of an antigen recognition structural domain driven by an SFFV promoter to express, a CD28 transmembrane structural domain and a DAP10 costimulatory signal structural domain. According to the structural design, the expression efficiency of the CAR in the gamma delta-T cells can be remarkably improved, and the recognition capability of the gamma delta-T cells on specific antigens and the tumor cell killing activity are enhanced, so that the maximization of the anti-tumor efficiency is realized.

The invention provides a system that comprises pharmaceutical agents for use in immunotherapy for reducing the side-effects of an antigen-recognizing receptor against antigen-expressing non-target cells in an individual. The system includes an antigen-recognizing receptor that specifically recognizes an antigen on target cells and at least on one hematopoietic cell type in the individual. The antigen-recognizing receptor is exemplified by chimeric antigen receptors (CAR) be expressed on the surface of an immune effector cells. The system also includes hematopoietic cells resistant to recognition of the same antigen by the antigen-recognizing receptor.

This invention provides a bispecific chimeric antigen receptor targeting BCMA-CD19 and its application, wherein the bispecific chimeric antigen receptor comprises an extracellular antigen recognition domain; wherein: the extracellular antigen recognition domain comprises an anti-BCMA extracellular antigen recognition domain and an anti-CD19 extracellular antigen recognition domain; the anti-CD19 extracellular antigen recognition domain comprises CD19VH and CD19VL, which are selected from one of groups 1) to 8).

The application provides a monoclonal antibody for specifically detecting rotavirus and an application thereof, and is directed to epidemic strains of porcine rotavirus, and refers to the gene sequence of VP6 protein published in GenBank, further optimizes an antigen epitope, obtains a purified recombinant VP6 protein with antigenicity, and performs animal immunization, and successfully screens the monoclonal antibody capable of specifically recognizing the porcine rotavirus. The monoclonal antibody screened can effectively recognize the epidemic strains, has the broad-spectrum recognition, is superior to the commercially available antibody, has high antigen recognition target specificity, is low in non-specificity, and has clear sequence background, can be scaled up and produced, and has good commercial value.

The invention provides an anti-CDH17 antibody or an antigen binding fragment of the anti-CDH17 antibody. The anti-CDH17 antibody can be a double-epitope antibody obtained by construction. The anti-CDH17 antibody provided by the invention can be specifically combined with CDH17 protein, has a relatively strong CDH17 expression tumor cell killing effect, can be effectively internalized on CDH17 expression tumor cells, and can be prepared into ADC (Analog to Digital Converter) which is effectively internalized on CDH17 expression tumor cells and has high killing activity; particularly, compared with an antibody combined with a CDH17 single epitope, the double-epitope antibody disclosed by the invention has more accurate and multi-dimensional antigen recognition capability and higher targeting property.

The present invention inter alia relates to an antigen recognizing construct capable of binding to a Preferentially Expressed Antigen in Melanoma (FRAME) peptide, a T cell receptor having antigenic specificity for FRAME, a nucleic acid sequence encoding said antigen recognizing construct or T cell receptor, a vector comprising said nucleic acid sequence, and a host cell comprising said antigen recognizing construct or T cell receptor. The invention also relates to the antigen recognizing construct or T cell receptor, the nucleic acid sequence, vector or host cell for use in medicine or for use in detection, diagnosis, prognosis, prevention and / or treatment of a disease. Additionally, the present invention relates to a method of treating a disease as well as a pharmaceutical composition and a kit.

The presently disclosed subject matter provides cells, compositions and methods for enhancing immune responses toward tumor antigens. It relates to cells comprising an antigen-recognizing receptor (e.g., a HIT receptor) and an inhibitory polynucleotide. These cells have improved activity and / or efficiency.

The presently disclosed subject matter provides cells, compositions, and methods for enhancing immune responses to tumor antigens. These cells comprise a first antigen-recognizing receptor that targets CD70. These cells have improved activity and / or efficiency. The present invention also provides a method for reducing tumor burden in a subject with renal cell carcinoma, pancreatic cancer, or ovarian cancer, comprising administering to the subject an effective amount of cells comprising a TCR-like fusion molecule that targets CD70.

The present invention provides immunoresponsive cells, including T cells, cytotoxic T cells, regulatory T cells, and Natural Killer (NK) cells, expressing an antigen recognizing receptor and an inhibitory chimeric antigen receptor (iCAR). Methods of using the immunoresponsive cell include those for the treatment of neoplasia and other pathologies where an increase in an antigen-specific immune response is desired.

The present application belongs to the technical field of cellular immunization engineering, and particularly relates to a polypeptide specifically recognizing PSCA and application thereof. The polypeptide provided by the present application specifically recognizes PSCA and has good affinity performance. The polypeptide specifically targeting PSCA provided by the present application can mark PSCA positive cells, combine with PSCA antigen and PSCA positive cells, and can be used as a detection reagent for PSCA molecules and an in-vivo tracing labeling reagent. The polypeptide specifically targeting PSCA provided by the present application can also be used in an extracellular antigen recognition region of a chimeric antigen receptor, and can be used in an immune cell treatment drug targeting PSCA to kill malignant tumors expressing PSCA. The polypeptide specifically recognizing PSCA of the present application is derived from a natural full human antibody, and compared with a mouse-derived antibody, a chimeric antibody and a humanized antibody, the immunogenicity is greatly reduced, and the safety can be maximally ensured in clinical application.

A workflow is presented herein which includes methods and computational systems and devices for providing 3D computational models of potential off-target peptides each positioned in a groove of an MHC molecule ("MHC-off-target models"), quantifying structural similarity between each potential off-target peptide to a target peptide based on a comparison of the MHC-off-target models to a 3D computational model of a target MHC-peptide complex ("MHC-target model"), and ranking the potential off-target peptides based on a structural similarity metric. Example methods and systems can be applied to solve bioinformatics and treatment development problems. The present disclosure also relates to compositions that involve isolated peptides, e.g., MAGEA3168-176 and / or WT1126-134 off-target peptides, and the use of such compositions in methods for assessing off-target effects of antigen-recognition molecules that target a MAGEA3168-176 and / or WT1126-134 peptide, as well as for selecting antigen-recognition molecules and enriching samples for antigen-recognition molecules that specifically bind the MAGEA3168-176 and / or WT1126-134.